The unipolar depression market is crowded and highly genericized. The prominent use of SSRIs and, to a lesser extent, SNRIs as early-line treatments contributes to the challenges branded therapies…
Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy,…
The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio…
Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens continue to be the…
DRG Epidemiology’s coverage of endometrial cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key axial spondyloarthritis patient populations covering 171 countries and…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total symptomatic…
The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second…
Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx) was the only drug approved for advanced disease…
Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates…
Epilepsy, which afflicts approximately 4.7 million people in the major markets according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a…
A series of launches are expected to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market over the next 10 years and challenge the dominance of the TNF inhibitors; the impact…
The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in…
Acute myeloid leukemia (AML), the most common form of leukemia in adults, has historically been associated with poor five-year overall survival rates. AML is witnessing a paradigm shift from…
Clarivate Epidemiology's coverage of amyloidosis comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…